This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, L.
Right arrow Articles by Raviprakash, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L.
Right arrow Articles by Raviprakash, K.

 Previous Article  |  Next Article 

Journal of Virology, November 2007, p. 11634-11639, Vol. 81, No. 21
0022-538X/07/$08.00+0     doi:10.1128/JVI.00996-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques{triangledown}

Lan Chen,1 Dan Ewing,1 Hemavathy Subramanian,1 Karla Block,1 Jonathan Rayner,3 Kimberly D. Alterson,2 Martha Sedegah,1 Curtis Hayes,1 Kevin Porter,1,2 and Kanakatte Raviprakash1,2*

Viral Diseases Department, Naval Medical Research Center, Silver Spring, Maryland,1 Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland,2 Alphavax Inc., Research Triangle Park, North Carolina3

Received 8 May 2007/ Accepted 8 August 2007

A candidate vaccine (D1ME-VRP) expressing dengue virus type 1 premembrane and envelope proteins in a Venezuelan equine encephalitis (VEE) virus replicon particle (VRP) system was constructed and tested in conjunction with a plasmid DNA vaccine (D1ME-DNA) expressing identical dengue virus sequences. Cynomolgus macaques were vaccinated with three doses of DNA (DDD), three doses of VRP (VVV group), or a heterologous DNA prime-VRP boost regimen (DDV) using two doses of DNA vaccine and a third dose of VRP vaccine. Four weeks after the final immunization, the DDV group produced the highest dengue virus type 1-specific immunoglobulin G antibody responses and virus-neutralizing antibody titers. Moderate T-cell responses were demonstrated only in DDD- and DDV-vaccinated animals. When vaccinated animals were challenged with live virus, all vaccination regimens showed significant protection from viremia. DDV-immunized animals were completely protected from viremia (mean time of viremia = 0 days), whereas DDD- and VVV-vaccinated animals had mean times of viremia of 0.66 and 0.75 day, respectively, compared to 6.33 days for the control group of animals.

* Corresponding author. Mailing address: Viral and Rickettsial Diseases Department, Naval Medical Research Center, Rm. 3N71, 503 Robert Grant Avenue, Silver Spring, MD 20910. Phone: (301) 319-7454. Fax: (301) 319-7451. E-mail: raviprakashk{at}nmrc.navy.mil

{triangledown} Published ahead of print on 22 August 2007.

Journal of Virology, November 2007, p. 11634-11639, Vol. 81, No. 21
0022-538X/07/$08.00+0     doi:10.1128/JVI.00996-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Raviprakash, K., Wang, D., Ewing, D., Holman, D. H., Block, K., Woraratanadharm, J., Chen, L., Hayes, C., Dong, J. Y., Porter, K. (2008). A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus. J. Virol. 82: 6927-6934 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»